
<DOC>
<DOCNO>WT02-B08-80</DOCNO>
<DOCOLDNO>IA072-000460-B045-43</DOCOLDNO>
<DOCHDR>
http://www.cinp.aust.com:80/tuepres.htm 203.108.64.146 19970121030710 text/html 49763
HTTP/1.0 200 OK
Date: Tue, 21 Jan 1997 02:58:20 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 49591
Last-modified: Tue, 18 Jun 1996 07:21:19 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE></TITLE>
</HEAD>
<BODY BGCOLOR="#fff2f7" ALINK="#ff0000">
<H5><CENTER><BR>
<BR>
<A HREF="index.htm#anchor689408"><IMG SRC="files.gif/smanlog.gif" WIDTH=
"62" HEIGHT="57" ALIGN="BOTTOM" NATURALSIZEFLAG="3"></A></CENTER>
</H5>
<H5><BR>
<BR>
<BR>
XX TH C.I.N.P. CONGRESS<BR>
WORLD CONGRESS CENTRE MELBOURNE</H5>
<HR>
<H2>TUESDAY JUNE 25, 1996</H2>
<HR>
<H4>ROOM CODES:</H4>
LA = LA TROBE THEATRE, H2 = HOWQUA 2, H3 = HOWQUA 3, O1 = OTWAY 1, O2 =<BR>
OTWAY 2, C1 = CORRYONG 1,<BR>
C2-5 = CORRYONG 2-5, JB = JOHN BATMAN THEATRE, B1 = BELLARINE 1, B2 =<BR>
BELLARINE 2, B3 = BELLARINE 3,<BR>
B4 = BELLARINE 4, B5 = BELLARINE 5, B7 = BELLARINE 7 
<H4>PRESENTATION CODES:</H4>
BW = BREAKFAST WORKSHOP, L = PLENARY LECTURE, P = POSTER PRESENTATION,<BR>
O = ORAL/FREE COMMUNICATION, S = SYMPOSIA<BR>
<HR><B>DAY Tuesday TIME 0730-0830<BR>
<BR>
ROOM LA</B><BR>
<BR>
SESSION HEADING Breakfast Workshop<BR>
Supported by an Educational Grant from Akzo Nobel<BR>
<BR>
BW-2 Tolerability of Antidepressants: The<BR>
Role of Serotonin Receptors<BR>
<HR><B>DAY Tuesday TIME 1130-1230<BR>
<BR>
ROOM JB</B><BR>
<BR>
SESSION HEADING Plenary Lecture<BR>
<BR>
L-2-0 Carlsson, Arvid 
<BLOCKQUOTE>Recent Advances in the Therapeutics of Schizophrenia: Is Dopamine
Still Relevant?</BLOCKQUOTE>
<HR><B>DAY Tuesday TIME 1230-1330<BR>
<BR>
ROOM JB</B><BR>
<BR>
SESSION HEADING Plenary Lecture<BR>
<BR>
L-3-0 Furness, John B 
<BLOCKQUOTE>Neuropeptides and Their Receptors</BLOCKQUOTE>
<HR><B>DAY Tuesday TIME 0830-1100<BR>
<BR>
ROOM H2</B><BR>
<BR>
SESSION HEADING Addiction II<BR>
<BR>
O-9-1 Hurd, Yasmin L 
<BLOCKQUOTE>The Role of in Vivo Amygdala Dopamine to Cocaine Self-Administration</BLOCKQUOTE>
<BR>
O-9-2 Fratta, Walter 
<BLOCKQUOTE>Gamma-Hydroxybutyric Acid Alters Intravenous Cocaine Self-Administration
in Rats</BLOCKQUOTE>
<BR>
O-9-3 Martin-Iverson, Mathew T 
<BLOCKQUOTE>Occupation of D1, D2 and 5HT2 Receptors and Behavioural Sensitisation
to Cocaine</BLOCKQUOTE>
<BR>
O-9-4 Foltin, Richard W <BR>
Smoked or I.V. Cocaine Binges in.Humans: Is There a &quot;Crash&quot;?<BR>
<BR>
O-9-5 White, Jason M <BR>
Determinants of Withdrawal in a Methadone Maintenance Population<BR>
<BR>
O-9-6 Bennie, Ernest H 
<BLOCKQUOTE>A Rapid Discontinuation of Opiates and Benzodiazepines in Dependent
Patients</BLOCKQUOTE>
<BR>
O-9-7 Lin, Shih-Ku 
<BLOCKQUOTE>Lofexidine in the Treatment of Heroin Withdrawal - A Comparative
Study With Clonidine</BLOCKQUOTE>
<BR>
O-9-8 Woldbye, David PD 
<BLOCKQUOTE>Neuropeptide Y AttenuatesNaloxone-Precipitated Morphine-Withdrawal
in Rats</BLOCKQUOTE>
<BR>
O-9-9 Liu, Yia-Ping 
<BLOCKQUOTE>Striatal Adenosine-Dopamine Modulation In Morphine Dependence
and Withdrawal</BLOCKQUOTE>
<BR>
O-9-10 Zernig, Gerald 
<BLOCKQUOTE>Clocinnamox Inhibits Heroin-Stimulated Nucleus Accumbens Dopamine
Overflow</BLOCKQUOTE>
<HR><B>DAY Tuesday TIME 0830-1100<BR>
<BR>
ROOM H3</B><BR>
<BR>
SESSION HEADING Obsessive compulsive disorder<BR>
<BR>
O-10-1 Hojaij, Carlos R 
<BLOCKQUOTE>Panic Attack as an EPI-Phenomenon of the Phobic-Obsessive- Compulsive
Disease</BLOCKQUOTE>
<BR>
O-10-2 Muller, Norbert 
<BLOCKQUOTE>Biological and Psychopathological Comparison of OCD and Tourette
Syndrome</BLOCKQUOTE>
<BR>
O-10-3 Wynchank, Dora 
<BLOCKQUOTE>Fluoxetine Treatment of Acral Lick Dermatitis in Dogs: A Placebo
Controlled Randomised Double Blind Trial</BLOCKQUOTE>
<BR>
O-10-4 Ebert, Dieter 
<BLOCKQUOTE>Proton Magnetic Resonance Spectroscopy in Obssesive Compulsive
Disorder</BLOCKQUOTE>
<BR>
O-10-5 Lucey, James V 
<BLOCKQUOTE>Cerebral Blood Flow and WCST in OCD</BLOCKQUOTE>
<BR>
O-10-6 Monteleone, Palmiero 
<BLOCKQUOTE>Serotonergic Function in Obsessive-Compulsive Disorder</BLOCKQUOTE>
<BR>
O-10-7 Pigott, Teresa A 
<BLOCKQUOTE>OCD: Comparisons of SRI Treatment</BLOCKQUOTE>
<BR>
O-10-8 Stein, Dan J 
<BLOCKQUOTE>Use of Citalopram, A Serotonin Selective Reuptake Inhibitor
in OCD</BLOCKQUOTE>
<BR>
<HR><B>DAY Tuesday TIME 0830-1100<BR>
<BR>
ROOM C1</B><BR>
<BR>
SESSION HEADING Movement Disorders<BR>
<BR>
O-11-1 Gardos, George 
<BLOCKQUOTE>Long Term Course of TardiveDyskinesia</BLOCKQUOTE>
<BR>
O-11-2 Annable, Lawrence 
<BLOCKQUOTE>Neuroleptic-Induced Extrapyramidal Symptoms: Factor Structure</BLOCKQUOTE>
<BR>
O-11-3 Lambert, Tim 
<BLOCKQUOTE>Gates: A New Instrument for the Clinical and Research Assessment
of Neuroleptic-Induced Movement Disorders</BLOCKQUOTE>
<BR>
O-11-4 Laugharne, Jon De 
<BLOCKQUOTE>Informing Patients about Tardive Dyskinesia: A Survey of Clinicians'
Attitudes</BLOCKQUOTE>
<BR>
O-11-5 Smith, Michael W 
<BLOCKQUOTE>Tardive Dyskinesia and Ethnicity: Review of the Literature</BLOCKQUOTE>
<BR>
O-11-6 McCreadie, Robin G 
<BLOCKQUOTE>Abnormal Movements in Never Medicated Indian Schizophrenic Patients</BLOCKQUOTE>
<BR>
O-11-7 Ananth, Jambur 
<BLOCKQUOTE>CYP2D6, Genotype, Phenotype and Tardive Dyskinesia</BLOCKQUOTE>
<BR>
O-11-8 Rosengarten, Helen 
<BLOCKQUOTE>A Phosphoinositide Linked Dopamine Receptor Mediates Dyskinetic
Jaw Movements in Rats</BLOCKQUOTE>
<BR>
O-11-9 Aoba, Anri 
<BLOCKQUOTE>A Double-Blind, Assessment of Carteolol, in the Treatment of
Neuroleptic-Induced Akathisia</BLOCKQUOTE>
<BR>
<HR><B>DAY Tuesday TIME 1330-1600<BR>
<BR>
ROOM H2</B><BR>
<BR>
SESSION HEADING Neuroimaging<BR>
<BR>
O-12-1 Kapur, Shitij 
<BLOCKQUOTE>Is Loxapine an 'Atypical' Antipsychotic: A Pet Study of the
In Vivo 5-HT2 and D2 Occupancy</BLOCKQUOTE>
<BR>
O-12-2 Morris, Philip L 
<BLOCKQUOTE>A Pet Activation Study of Major Depression</BLOCKQUOTE>
<BR>
O-12-3 Kapur, Shitij 
<BLOCKQUOTE>Relationship Between D2 Receptor Occupancy and Plasma Haloperidol:
A Pet Study</BLOCKQUOTE>
<BR>
O-12-4 Kasper, Siegfried 
<BLOCKQUOTE>D2-Receptor Imaging in Atypical Neuroleptics</BLOCKQUOTE>
<BR>
O-12-5 Kapur, Shitij 
<BLOCKQUOTE>SDA Antipsychotics - From Theory to Clinical Practice: Lessons
PET Neuroimaging</BLOCKQUOTE>
<BR>
O-12-6 Okubo, Yoshiro 
<BLOCKQUOTE>PET Studies of D1 and D2 Dopamine Receptors in Schizophrenic
Patients</BLOCKQUOTE>
<BR>
O-12-7 O'Sullivan, Brendan T 
<BLOCKQUOTE>A Pet Study of Attention and Working Memory: Subspecialisation
of Human Prefrontal Cortex</BLOCKQUOTE>
<BR>
O-12-8 Remington, Gary J 
<BLOCKQUOTE>Risperidone and the Relationship Between D2 Receptor Occupancy
and Plasma Levels</BLOCKQUOTE>
<BR>
O-12-8 Nakashima, Yoshifumi 
<BLOCKQUOTE>5HT2-Receptor Occupancy of Antipsychotic Drugs</BLOCKQUOTE>
<BR>
O-12-9 Yates, Roger A 
<BLOCKQUOTE>Time Course for Dopamine and Serotonin Receptor Occupancy in
the Brain of Schizophrenic PatientsFollowing Dosing with 150 MG 'Seroquel'
TID</BLOCKQUOTE>
<BR>
<HR><B>DAY Tuesday TIME 1330-1600<BR>
<BR>
ROOM H3</B><BR>
<BR>
SESSION HEADING Animal models<BR>
<BR>
O-13-1 Monti, Jaime M 
<BLOCKQUOTE>Sleep and Walking During Acute Histamine H3-Agonist BP 2.94
or H3-Antagonist Carboperamide (MR 16155) Administration in Rats</BLOCKQUOTE>
<BR>
O-13-2 Woldbye, David PD 
<BLOCKQUOTE>Neuropeptide Y Inhibits Hippocampal Seizures and Wet Dog Shakes</BLOCKQUOTE>
<BR>
O-13-3 Skarsfeldt, T 
<BLOCKQUOTE>Differentiation of Classical and Novel Antipsychotics Using
Animal Models</BLOCKQUOTE>
<BR>
O-13-4 Becker, Axel 
<BLOCKQUOTE>Kindling of the Dorsal and theVentral Hippocampus and its Effects
on Learning Performance in Rats</BLOCKQUOTE>
<BR>
O-13-5 Andrews, John 
<BLOCKQUOTE>Differential Effects of Mirtazapineand Imipramine on CognitivePerformance
in Male Long Evans Rats</BLOCKQUOTE>
<BR>
O-13-6 Alvarez, Anton 
<BLOCKQUOTE>Protective Effects of Anapsos in Rats With Hippocampal Neurodegeneration</BLOCKQUOTE>
<BR>
O-13-7 Bobkiewicz-Kozlowska, Teresa 
<BLOCKQUOTE>The Comparison of Lisinopril andCaptopril Activities on Cerebral
Blood Flow in SHR Rats</BLOCKQUOTE>
<BR>
O-13-8 Allain, Herve J 
<BLOCKQUOTE>Neuroprotective Effects of DopamineReceptors Agonists in Cerebral
Ischemia</BLOCKQUOTE>
<BR>
O-13-9 Conway, Elizabeth L 
<BLOCKQUOTE>Effects of Imidazoline2 Receptor Ligands on Neuronal Damage
in Global Ischaemia in the Rat</BLOCKQUOTE>
<BR>
<HR><B>DAY Tuesday TIME 1330-1600<BR>
<BR>
ROOM C1</B><BR>
<BR>
SESSION HEADING Circadian rhythms and melatonin<BR>
<BR>
O-14-1 Sidorov, Pavel I 
<BLOCKQUOTE>Posttraumatic Stress Disorders Among the Afghanistan War Veterans</BLOCKQUOTE>
<BR>
O-14-2 Chung, Moon Yong 
<BLOCKQUOTE>Twenty Four - Hour Urinary Monoamine Excretion in Posttrumatic
Stress Disorder</BLOCKQUOTE>
<BR>
O-14-3 Nerush, Peter 
<BLOCKQUOTE>A Influence of Psychotropic Agents on Process of Brain Desadaptation
in Emotional Stress States</BLOCKQUOTE>
<BR>
O-14-4 Kvetnansky, Richard 
<BLOCKQUOTE>Regulation of Gene Expression of Catecholamine Synthetic Enzymes
in Brain and Periphery of Rats During Stress</BLOCKQUOTE>
<BR>
O-14-5 Popova, Nina K Serotonin Metabolism and 5-HT1A 
<BLOCKQUOTE>Receptors in Genetically Defined Fear-Induced Aggression</BLOCKQUOTE>
<BR>
O-14-6 Kulkarni, Shrinivas K 
<BLOCKQUOTE>GABA-A Receptor Mediated Antistress Activity of Neurosteroids
in Mice</BLOCKQUOTE>
<BR>
O-14-7 Bing, Ola Anticonflict 
<BLOCKQUOTE>Effects of High Doses of Testosterone in Male Wistar Rats</BLOCKQUOTE>
<BR>
O-14-8 Wongwitdecha, Noppamars 
<BLOCKQUOTE>Social Isolation Increases the Effects of Paroxetine in the
Forced Swimming Test</BLOCKQUOTE>
<BR>
O-14-9 Barton, Cheryl L 
<BLOCKQUOTE>Attenutation of Stress Induced Cortical Dopamine Neurons By
L-701, 324, A Selective Glycine/NMDA Antagonist is Mediated Via An Interaction
With Gabaergic Neurons</BLOCKQUOTE>
<BR>
O-14-10 Karle, Jesper Antisense Studies of Rat Brain GABA A 
<BLOCKQUOTE>Receptor Structure and Function in Vivo</BLOCKQUOTE>
<BR>
<BR>
<HR><B>DAY Tuesday TIME 1330-1600<BR>
<BR>
ROOM O1</B><BR>
<BR>
SESSION HEADING Circadian rhythms and melatonin<BR>
<BR>
O-15-1 Wirz-Justice, Anna M 
<BLOCKQUOTE>Surprising Drug Effects on the Circadian Rest-Activity Cycle
inb Schizophrenia</BLOCKQUOTE>
<BR>
O-15-2 Egami, Hideaki 
<BLOCKQUOTE>The Effects of Ethanol on the Circadian Rhythms of Locomotor
Activity and Body Temperature in Rats</BLOCKQUOTE>
<BR>
O-15-3 Wirz-Justice, Anna M 
<BLOCKQUOTE>Chronobiotic Versus Hypnotic Properties of Melatonin</BLOCKQUOTE>
<BR>
O-15-4 Hirano, Takashi 
<BLOCKQUOTE>Effects of h-CRH on Sleep and Body Temperature Rhythms</BLOCKQUOTE>
<BR>
O-15-5 Wirz-Justice, Anna M 
<BLOCKQUOTE>Timed Melatonin Administration on Circadian Rhythms and Vigilance
States</BLOCKQUOTE>
<BR>
O-15-6 Steiger, Axel 
<BLOCKQUOTE>Sleep EEG and Nocturnal Hormone Secretion After Traumatic Brain
Injury</BLOCKQUOTE>
<BR>
O-15-7 Silver, Henry Melatonin 
<BLOCKQUOTE>Secretion ExhibitsTolerance During Chronic Fluvoxamine treatment
in Medicated Schizophrenic Patients</BLOCKQUOTE>
<BR>
O-15-8 Nathan, Pradeep J Serotonergic 
<BLOCKQUOTE>Control of Melatonin Secretion: The Role of 5-HT1A Receptors</BLOCKQUOTE>
<BR>
<HR><B>DAY Tuesday TIME 0830-1100<BR>
<BR>
ROOM O2</B><BR>
<BR>
SESSION HEADING Post-traumatic stress disorder<BR>
Chair: P Morris (Australia) Co-chair: R Yehuda (USA)<BR>
<BR>
S-19-1 Raphael, Beverley 
<BLOCKQUOTE>The Assessment of PISD in Veterans</BLOCKQUOTE>
<BR>
S-19-2 McFarlane, Sandy 
<BLOCKQUOTE>Biological Paradigms of the Attentional Processing in Post Traumatic
Stress Disorder</BLOCKQUOTE>
<BR>
S-19-3 Yehuda, Rachel Neuroendocrine 
<BLOCKQUOTE>Alterations in PTSD</BLOCKQUOTE>
<BR>
S-19-4 Jackson, Richard V Naloxone 
<BLOCKQUOTE>Reveals Decreased Threshold for Hypothalamic CRH Release in
PTSD</BLOCKQUOTE>
<BR>
S-19-5 Hopwood, M 
<BLOCKQUOTE>The Modified Dexamethasone Suppression Test (mDST) in Chronic
PTSD</BLOCKQUOTE>
<BR>
S-19-6 Morris, Philip LP 
<BLOCKQUOTE>Central Noradrenergic and Serotonergic Neurotransmitter Function
in Chronic PTSD</BLOCKQUOTE>
<BR>
<HR><B>DAY Tuesday TIME 0830-1100<BR>
<BR>
ROOM B2</B><BR>
<BR>
SESSION HEADING The diminishing correlation between drug plasma concentration
and<BR>
effects: fact or fallacy?<BR>
Chair: L De Vane (USA) Co-chair: T Norman (Australia)<BR>
<BR>
S-20-1 Balant, Luc P 
<BLOCKQUOTE>Concentration / Effect Relationships in Clinical Psychopharmacology:
Clinical Trials Designs</BLOCKQUOTE>
<BR>
S-20-2 Ketter, Terence 
<BLOCKQUOTE>A Clinical Pharmacokinetic Update on Anticonvulsants</BLOCKQUOTE>
<BR>
S-20-3 DeVane, Lindsay 
<BLOCKQUOTE>Theoretical Considerations of Dose/Concentrations/Effect Relationships:
Direct and Indirect Pharmocokinetic/Dynamic Models</BLOCKQUOTE>
<BR>
S-20-4 Kato, Tadafumi 
<BLOCKQUOTE>Measurement of Lithium Brain Concentration by Li-7 MRS and Correlation
with Effects</BLOCKQUOTE>
<BR>
S-20-5 Norman, Trevor R 
<BLOCKQUOTE>Clinical Pharmacokinetics of Serotonin Reuptake Inhibitor and
Newer Antipsychotic Drugs</BLOCKQUOTE>
<BR>
<HR><B>DAY Tuesday TIME 0830-1100<BR>
<BR>
ROOM LA</B><BR>
<BR>
SESSION HEADING Predictors of response to SSRI's<BR>
Sponsored by Eli Lilly<BR>
Chair: S Montgomery (UK) Co-chair: D Marazziti (Italy)<BR>
<BR>
S-21-1 Marazziti, Donatella 
<BLOCKQUOTE>Biological Predictors of Response</BLOCKQUOTE>
<BR>
S-21-2 Perugi, Giulio 
<BLOCKQUOTE>Long Term Treatment of Panic Disorder-Agoraphobia</BLOCKQUOTE>
<BR>
S-21-3 Zohar, Joseph 
<BLOCKQUOTE>Predictors of Response in Obsessive-Compulsive Disorder</BLOCKQUOTE>
<BR>
S-21-4 Akiskal, Hagop S 
<BLOCKQUOTE>Temperament and Pharmacological Response in Depression</BLOCKQUOTE>
<BR>
S-21-5 Montgomery, Stuart 
<BLOCKQUOTE>A Clinical Predictions of Response to Treatments in Mood Disorders</BLOCKQUOTE>
<BR>
<HR><B>DAY Tuesday TIME 0830-1100<BR>
<BR>
ROOM B3</B><BR>
<BR>
SESSION HEADING New advances in the biology of corticosteroid receptors:
relevance to<BR>
development, neurotransmission and behaviour<BR>
Chair: R De Kloet (The Netherlands) Co-chair: H Akil (USA)<BR>
<BR>
S-22-1 Cole, Timothy J 
<BLOCKQUOTE>Consequences of Corticosteroid Receptor Ablation</BLOCKQUOTE>
<BR>
S-22-2 de Kloet, Ronald 
<BLOCKQUOTE>Brain Corticosteroid Receptors and Stress System Disorders</BLOCKQUOTE>
<BR>
S-22-3 Krozowski, Zig S Regeneration and Inactivation of<BR>
Bioactive Corticosteroids: Windows<BR>
for Neuropharmaceutical Intervention<BR>
<BR>
S-22-4 Vazquez, Delia M 
<BLOCKQUOTE>Mineralocorticoid Receptor mRNA Variants in the Developing Hippocampus:
Distribution and Regulation</BLOCKQUOTE>
<BR>
S-22-5 Sakai, Randall R 
<BLOCKQUOTE>Intracerebral Antisense Oligonucleotides Reduce Mineralocorticoid-Induced
Ingestive Behaviours</BLOCKQUOTE>
<BR>
<HR><B>DAY Tuesday TIME 0830-1100<BR>
<BR>
ROOM B4</B><BR>
<BR>
SESSION HEADING John Cade Symposium on lithium - Part 1<BR>
Chair: G Johnson (Australia) Co-chair: R Lenox (USA)<BR>
<BR>
S-23-1 Johnson, Gordon F 
<BLOCKQUOTE>Lithium Treatment in Psychiatry:Early Development and Recent
Observations</BLOCKQUOTE>
<BR>
S-23-2 Gershon, Samuel 
<BLOCKQUOTE>The Lithium Ion: A Foundation for Psychopharmacological Specificity</BLOCKQUOTE>
<BR>
S-23-3 Dunner, David L 
<BLOCKQUOTE>Rapid Cycling Bipolar Disorder: An Update</BLOCKQUOTE>
<BR>
S-23-4 Bowden, Charles L 
<BLOCKQUOTE>Lithium in Comparison to Valproate and Carbamezepine</BLOCKQUOTE>
<BR>
S-23-5 Post, Robert 
<BLOCKQUOTE>Title to be advised</BLOCKQUOTE>
<BR>
<HR><B>DAY Tuesday TIME 0830-1100<BR>
<BR>
ROOM JB</B><BR>
<BR>
SESSION HEADING Long-term use of novel antipsychotics: Issues and solutions<BR>
Sponsored by Janssen-Cilag, Organon<BR>
Chair: J Kane (USA) Co-chair: N Keks (Australia)<BR>
<BR>
S-24-1 Kane, John M 
<BLOCKQUOTE>Important Factors in Long-term Maintenance Therapy</BLOCKQUOTE>
<BR>
S-24-2 Remington, Gary First Episode Psychosis: Diagnosis,<BR>
Treatment and the Role of New<BR>
Antipsychotics<BR>
<BR>
S-24-3 Keks, Nicholas 
<BLOCKQUOTE>A Long-Term Use of Novel Antipsychotics Side-Effects, Safety
and the Risks of Non-Compliance</BLOCKQUOTE>
<BR>
S-24-4 Grebb, Jack 
<BLOCKQUOTE>Clinical Experience of Relapse Prevention With Novel Antipsychotics
in Chronic Schizophrenia</BLOCKQUOTE>
<BR>
S-24-5 Leff, Julian Aiding 
<BLOCKQUOTE>Resocialisation of the Complaint Chronic Psychotic Patient</BLOCKQUOTE>
<BR>
<HR><B>DAY Tuesday TIME 0830-1100<BR>
<BR>
ROOM B5</B><BR>
<BR>
SESSION HEADING Molecular mechanisms involved in the therapeuticn applications
of<BR>
drugs which inhibit neuronal transporters<BR>
Chair: S Langer (France)<BR>
<BR>
S-25-1 Langer, Saloman Z 
<BLOCKQUOTE>The Serotonin Tranporter: From Molecular Pharmacology to Therapeutics</BLOCKQUOTE>
<BR>
S-25-2 Jones, Sara 
<BLOCKQUOTE>Title to be advised</BLOCKQUOTE>
<BR>
S-25-3 Lesch, Klaus-Peter 
<BLOCKQUOTE>Neuronal Transporters as Candidate Genes for Affective Disorders</BLOCKQUOTE>
<BR>
S-25-4 De Montigny, Claude 
<BLOCKQUOTE>Effect of Long-Term Antidepressant Treatment on Presynaptic
Receptors and Monoamine Transporters</BLOCKQUOTE>
<BR>
S-25-5 Potter, William Z 
<BLOCKQUOTE>Clinical Onset of Antidepressant Action: Implications for New
Drug Development</BLOCKQUOTE>
<BR>
<HR><B>DAY Tuesday TIME 0830-1100<BR>
<BR>
ROOM B7</B><BR>
<BR>
SESSION HEADING Pharmacotherapy of affective disorders in women - Part 1<BR>
Sponsored by International Pharmaceuticals Group, Pfizer Inc<BR>
Chair: U Halbreich (USA) Co-chair: L Dennerstein (Australia)<BR>
<BR>
S-26-1 Halbreich, Uriel M 
<BLOCKQUOTE>The Continuum of Affective Disorders in Women - Diagnostic and
Therapeutic Implications</BLOCKQUOTE>
<BR>
S-26-2 Vale, Wylie W CNS 
<BLOCKQUOTE>Roles of CRF and Urocortin, Their Receptors and Binding Protein</BLOCKQUOTE>
<BR>
S-26-3 Yonkers, Kimberly 
<BLOCKQUOTE>A Gender Differences in the Response to Pharmacotherapy Among
Early Onset Dysthymics</BLOCKQUOTE>
<BR>
S-26-4 Freeman, Ellen W 
<BLOCKQUOTE>Mood Effects of Hormonal Interventions - Comparisons to Conventional
Antidepressants</BLOCKQUOTE>
<BR>
S-26-5 Stowe, Zachary N 
<BLOCKQUOTE>Psychopharmacology of Pregnant and Postpartum Women</BLOCKQUOTE>
<BR>
S-26-6 Steiner, Meir 
<BLOCKQUOTE>The Psychobiology of Female Specific Mood Disorders</BLOCKQUOTE>
<BR>
<HR><B>DAY Tuesday TIME 0830-1100<BR>
<BR>
ROOM O1</B><BR>
<BR>
SESSION HEADING Imidazoline receptors: CNS pharmacology and clinical relevance<BR>
Chair: A Halaris (USA) Co-chair: J Garcia-Sevilla (Spain)<BR>
<BR>
S-27-1 Halaris, Angelos 
<BLOCKQUOTE>E Platelet Immunoreactivity and Radioligand Binding to Imidazoline
Receptors in Depression</BLOCKQUOTE>
<BR>
S-27-2 Nutt, David J 
<BLOCKQUOTE>Imidazoline Receptors: CNS Pharmacology and Clinical Relevance</BLOCKQUOTE>
<BR>
S-27-3 Vauquelin, Georges 
<BLOCKQUOTE>P I1 and 12 Imidazoline Receptors in the Human Striatum: Comparison
to Other Species</BLOCKQUOTE>
<BR>
S-27-4 Musgrave, Ian Imidazoline 
<BLOCKQUOTE>Receptors, Possible Signal Transduction Mechanisms</BLOCKQUOTE>
<BR>
S-27-5 Piletz, John E 
<BLOCKQUOTE>Distribution and Regulation of Imidazoline Receptors in the
Brain</BLOCKQUOTE>
<BR>
<HR><B>DAY Tuesday TIME 0830-1100<BR>
<BR>
ROOM B</B>1<BR>
<BR>
SESSION HEADING Suicide<BR>
Chair: G Burrows (Australia) Co-chair: J Mann (USA)<BR>
<BR>
S-28-1 Burrows, Graham D 
<BLOCKQUOTE>Youth Suicide in Victoria: A Retrospective Study</BLOCKQUOTE>
<BR>
S-28-2 Gangat, Abie E 
<BLOCKQUOTE>Latrogenesis and Medication as Potential Factors in Suicide
and Depression</BLOCKQUOTE>
<BR>
S-28-3 Hrdina, Paul D Postmortem 
<BLOCKQUOTE>Brain and Platelet Receptor Changes in Suicide/Depression</BLOCKQUOTE>
<BR>
S-28-4 Pandey, Ghanshyam N G 
<BLOCKQUOTE>Proteins in the Postmortem Brain of Suicide Victims</BLOCKQUOTE>
<BR>
S-28-5 Pitchot, William R 
<BLOCKQUOTE>Low Serum Cholesterol, Suicide and Serotonin</BLOCKQUOTE>
<BR>
S-28-6 Mann, John 
<BLOCKQUOTE>Title to be advised</BLOCKQUOTE>
<BR>
<BR>
<HR><B>DAY Tuesday TIME 1330-1600<BR>
<BR>
ROOM O2</B><BR>
<BR>
SESSION HEADING Psychological and biological markers of OCD<BR>
Chair: J Zohar (Israel) Co-chair: M Flament (France)<BR>
<BR>
S-29-1 Flament, Martine F 
<BLOCKQUOTE>Pharmacological Treatment of OCD</BLOCKQUOTE>
<BR>
S-29-2 Blier, Pierre 
<BLOCKQUOTE>Role of the Terminal 5-HT Autoreceptor in the Orbitofrontal
Cortex in the Mechanism of Action of 5-HT Reuptake Inhibitors in OCD</BLOCKQUOTE>
<BR>
S-29-3 Zohar, Joseph 
<BLOCKQUOTE>New Insights to the Serotonin Hypothesis of OCD</BLOCKQUOTE>
<BR>
S-29-4 Baxter, Lewis R 
<BLOCKQUOTE>Specific Brain Systems in Obssesive-Compulsive Disorder Treatment</BLOCKQUOTE>
<BR>
S-29-5 Hollander, Eric 
<BLOCKQUOTE>New Developments in Impulsivity and Compulsivity</BLOCKQUOTE>
<BR>
<HR><B>DAY Tuesday TIME 1330-1600<BR>
<BR>
ROOM B1</B><BR>
<BR>
SESSION HEADING Are there anatomical anomalies in the brains of schizophrenics?<BR>
Lessons from post-mortem studies<BR>
Chair: W Bunney Jr. (USA) Co-chair: S Watson (USA)<BR>
<BR>
S-30-1 Meador-Woodruff, James H 
<BLOCKQUOTE>Dopamine Receptor Transcript Expression in Schizophrenia</BLOCKQUOTE>
<BR>
S-30-2 Kerwin, Robert W 
<BLOCKQUOTE>Glutamatergic Abnormalities in the Temporal Lobe in Schizophrenia</BLOCKQUOTE>
<BR>
S-30-3 Beckmann, Helmut 
<BLOCKQUOTE>Temporal Lobe Cytoarchitectural Pathology in Schizophrenia</BLOCKQUOTE>
<BR>
S-30-4 Jones, Edward G 
<BLOCKQUOTE>Altered Gene Expression for Receptors and Transmitters in Prefrontal
Cortex of Schizophrenics</BLOCKQUOTE>
<BR>
S-30-5 Kleinman, Joel E <BR>
The Neuropathology of Schizophrenia:Autoradiographic and in Situ Hybridization
Studies<BR>
<BR>
<HR><B>DAY Tuesday TIME 1330-1600<BR>
<BR>
ROOM JB</B><BR>
<BR>
SESSION HEADING Refractory depression: new issues Sponsored by Wyeth-Ayerst<BR>
International Inc.<BR>
Chair: R Joffe (Canada)<BR>
<BR>
S-31-1 Sellers, Edward M 
<BLOCKQUOTE>Metabolism, Kinetics and Interactions in Treating Refractory
Depression</BLOCKQUOTE>
<BR>
S-31-2 Price, Lawrence H 
<BLOCKQUOTE>Treatment-Resistant Depression:Resistant and Complicated Depression</BLOCKQUOTE>
<BR>
S-31-3 Joffe, Russell T 
<BLOCKQUOTE>Refractory Depression: First Line Treatment</BLOCKQUOTE>
<BR>
S-31-4 Keller, Martin B 
<BLOCKQUOTE>Treatment Refractory Depression: Long Term Issues</BLOCKQUOTE>
<BR>
S-31-5 Burrows, Graham D 
<BLOCKQUOTE>Implications of Comorbidity for theTreatment of Depression</BLOCKQUOTE>
<BR>
<HR><B>DAY Tuesday TIME 1330-1600<BR>
<BR>
ROOM LA</B><BR>
<BR>
SESSION HEADING The mechanism of action of novel antipsychotics<BR>
Sponsored by Eli Lilly<BR>
Chair: H Meltzer (USA) Co-chair: A Carlsson (Sweden)<BR>
<BR>
S-32-1 Fibiger, Hans C 
<BLOCKQUOTE>Immediate Early Gene Expression and the Mechanisms of Action
of Atypical Antipsychotics</BLOCKQUOTE>
<BR>
S-32-2 Meltzer, Herbert Y 
<BLOCKQUOTE>Multiple Serotonin/Dopamine Receptor Interactions Contribute
to Atypical Antipsychotic Drug Action</BLOCKQUOTE>
<BR>
S-32-3 Waters, Nicholas 
<BLOCKQUOTE>Brain Biochemistry in the Normal and Hypoglutamatergic State
- What Distinguishes Atypical From Typical Antipsychotics? A Multivariate
Approach</BLOCKQUOTE>
<BR>
S-32-4 Svensson, Torgny H 
<BLOCKQUOTE>Stabilization of Brain DA Systems in Psychosis by Concomitant
5-HT2 and Alpha1-Receptor Blockade</BLOCKQUOTE>
<BR>
<HR><B>DAY Tuesday TIME 1330-1600<BR>
<BR>
ROOM B4</B><BR>
<BR>
SESSION HEADING John Cade Symposium on lithium - Part 2<BR>
Chair: R Lenox (USA) Co-chair: G Johnson (Australia)<BR>
<BR>
S-33-1 Mork, Arne 
<BLOCKQUOTE>Actions of Lithium on Brain Adenylyl Cyclase: Role of Magnesium</BLOCKQUOTE>
<BR>
S-33-2 Lenox, Robert H 
<BLOCKQUOTE>Marcks: A Key to the Long-Term Therapeutic Action of Mood Stabilizers
in the Brain</BLOCKQUOTE>
<BR>
S-33-3 Manji, Husseini K 
<BLOCKQUOTE>Regulation of Transmembrane Signalling Systems by Mood Stabilizing
Agents: Therapeutic Implications</BLOCKQUOTE>
<BR>
S-33-4 Belmaker, R H 
<BLOCKQUOTE>The Inositol Depletion Hypothesis: Promise and Problems</BLOCKQUOTE>
<BR>
S-33-5 Perez, Jorge 
<BLOCKQUOTE>Lithium Effects on Protein Phosphorylation in Bipolar and Healthy
Subjects</BLOCKQUOTE>
<BR>
<HR><B>DAY Tuesday TIME 1330-1600<BR>
<BR>
ROOM B5</B><BR>
<BR>
SESSION HEADING Neurotrophic factors: neuropsychiatric implications<BR>
Chair: M Sandler (UK)<BR>
<BR>
S-34-1 Shooter, Eric M NGF, 
<BLOCKQUOTE>How it All Began and How Modern Technologies Confirm and Expand
the Original Hypothesis</BLOCKQUOTE>
<BR>
S-34-2 Thoenen, Hans 
<BLOCKQUOTE>Modulation of Activity-Dependent Neuronal Plasticity: A New
Facet of Neurotrophin Action</BLOCKQUOTE>
<BR>
S-34-3 Lindsay, Ronald M 
<BLOCKQUOTE>Neurotrophic Factors: Biology &amp; Clinical Potential</BLOCKQUOTE>
<BR>
S-34-4 Post, Robert M 
<BLOCKQUOTE>Opposing Effects of Stress and Antidepressants on Neurotrophic
Factors</BLOCKQUOTE>
<BR>
S-34-5 Duman, Ronald S A 
<BLOCKQUOTE>Role for Neurotrophins in the Action of Chronic Antidepressant
Treatments</BLOCKQUOTE>
<BR>
<HR><B>DAY Tuesday TIME 1330-1600<BR>
<BR>
ROOM B7</B><BR>
<BR>
SESSION HEADING Pharmacotherapy of affective disorders in women - Part 2<BR>
Chair: U Halbreich (USA) Co-chair: L Dennerstein (Australia)<BR>
<BR>
S-35-1 Nadelson, Carol C 
<BLOCKQUOTE>Gender Differences in Health &amp; Mental Health: Pracitical
Implications</BLOCKQUOTE>
<BR>
S-35-2 Saletu, Bernd 
<BLOCKQUOTE>Estrogen in Postmenopausal Women With and Without Depression:
EEG, Endocrinological and Psychometric Studies</BLOCKQUOTE>
<BR>
S-35-3 Weizman, Abraham 
<BLOCKQUOTE>Gonadal Hormones, GABA and Benzodiazepine Receptors</BLOCKQUOTE>
<BR>
S-35-4 Stahl, Stephen M 
<BLOCKQUOTE>Estrogen and Thyroid Hormones as Adjuncts for Antidepressant
Treatment of Post-Menopausal Women</BLOCKQUOTE>
<BR>
S-35-5 Halbreich, Uriel M 
<BLOCKQUOTE>Pharmacotherapy of Depression in Women: Ethical, Conceptual
and Practical Considerations</BLOCKQUOTE>
<BR>
<HR><B>DAY Tuesday TIME 1330-1600<BR>
<BR>
ROOM B3</B><BR>
<BR>
SESSION HEADING New antiepileptic drugs and psychopharmacology<BR>
Chair: J Walden (Germany) Co-chair: D Van Calker (Germany)<BR>
<BR>
S-36-1 Van Calker, D Adenosine 
<BLOCKQUOTE>Receptors as a Target For Carbamazepine's Action in the Brain</BLOCKQUOTE>
<BR>
S-36-2 Walden, Jorg Calcium 
<BLOCKQUOTE>Antagonism as a Common Mode of Action of Some Antiepileptic
Drugs in the Treatment of Epilepsies and Affective Disorders</BLOCKQUOTE>
<BR>
S-36-3 Bowden, Charles L 
<BLOCKQUOTE>New Concepts in Mood Stabilization: Evidence for the Effectiveness
of Valproate and Lamotrigine</BLOCKQUOTE>
<BR>
S-36-4 Calabrese, C 
<BLOCKQUOTE>Lamotrigine in Treatment Refractory Manic Depression</BLOCKQUOTE>
<BR>
S-36-5 Emrich, Hinderk M 
<BLOCKQUOTE>Oxcarbazepine, Carbamazepine and Valproate in the Treatment
of Affective and Disintegrative Psychiatric Disorders</BLOCKQUOTE>
<BR>
<HR><B>DAY Tuesday TIME 1330-1600<BR>
<BR>
ROOM B2</B><BR>
<BR>
SESSION HEADING New perspectives on the schizophrenia spectrum<BR>
Chair: L Siever (USA)<BR>
<BR>
S-37-1 Mc Carley, Robert W 
<BLOCKQUOTE>Schizophrenia Spectrum Disorders: Electrophysiological &amp;
Structural MRI Features</BLOCKQUOTE>
<BR>
S-37-2 Cornblatt, Barbara A 
<BLOCKQUOTE>Childhood Predictors of Schizotypal Features in Non-Psychotic
Adults</BLOCKQUOTE>
<BR>
S-37-3 Siever, Larry J 
<BLOCKQUOTE>Neurobiology of the Schizophrenia Spectrum</BLOCKQUOTE>
<BR>
S-37-4 Battaglia, Marco M 
<BLOCKQUOTE>A Multidimensional Approach to Schizotypal Disorder</BLOCKQUOTE>
<BR>
S-37-5 Velakoulis, Dennis 
<BLOCKQUOTE>Hippocampal Volume Reduction and Cognitive Deficits: Course
From High Risk to Chronic Schizophrenia</BLOCKQUOTE>
<BR>
<HR><B>DAY Tuesday TIME 1600-1730<BR>
<BR>
ROOM C2-5</B><BR>
<BR>
SESSION HEADING Poster Presentations<BR>
<BR>
P-8-1 Jalenques, Isabelle Hypnotic 
<BLOCKQUOTE>Use in a Psychiatric Department</BLOCKQUOTE>
<BR>
P-8-2 Sugiyama, Takeshi 
<BLOCKQUOTE>Long-Term Use of Benzodiazepine Hypnotics</BLOCKQUOTE>
<BR>
P-8-3 Zyhlarz, Gerda M 
<BLOCKQUOTE>Sleep Studies in Insomnia Based on Generalized Anxiety Disorder
with Diphenhydramine/Lorazepam (Somnium R)</BLOCKQUOTE>
<BR>
P-8-4 Kaneta, Keiji 
<BLOCKQUOTE>The Effect of Trazodone on Sleep in Healthy Young Adults</BLOCKQUOTE>
<BR>
P-8-5 Patat, Alain A 
<BLOCKQUOTE>Effects of Zopiclone, Zolpidem and Flunitrazepam on Nocturnal
Psychomotor and Cognitive Functions in Normal Young Subjects</BLOCKQUOTE>
<BR>
P-8-6 Yoshimoto, Masaki 
<BLOCKQUOTE>Effects of Zolpidem, Triazolam and Zopiclone on REM Sleep and
Hippocampal Theta Activity in Rats</BLOCKQUOTE>
<BR>
P-8-7 Steiger, Axel 
<BLOCKQUOTE>Sleep Endocrine Effects of Neuropeptide Y in Men Reveal a GABAa-Agonistic
Action</BLOCKQUOTE>
<BR>
P-8-8 Yamada, Naoto 
<BLOCKQUOTE>Clinical and Chronobiological Effects of Sleep Deprivation on
Depressed Patients</BLOCKQUOTE>
<BR>
P-8-9 Himei, Akio Linkage 
<BLOCKQUOTE>Study of Narcolepsy in 7 Japanese Families</BLOCKQUOTE>
<BR>
P-8-10 McNulty, Owen M 
<BLOCKQUOTE>Acute Nocturnal Doses of Short-acting Benzodiazepines Suppress
Melatonin Secretion in Humans</BLOCKQUOTE>
<BR>
P-8-11 Nathan, Pradeep J 
<BLOCKQUOTE>The Relationship Between 5-HT and Melatonin in the Rat Pineal
Gland</BLOCKQUOTE>
<BR>
P-8-12 Saiz-Ruiz, Jeronimo 
<BLOCKQUOTE>Changes in Circadian Rhythm of Activity in Depression Model
Depending on Dark/Light Phase of Test Start</BLOCKQUOTE>
<BR>
P-8-13 Tsujimaru, Shusaku 
<BLOCKQUOTE>Effects of Vitamin B12 on the Lithium Carbonate-Induced Prolongation
of Free-Running Period in Rat Circadian Rhythms</BLOCKQUOTE>
<BR>
P-8-14 Asami, Takayasu 
<BLOCKQUOTE>Circadian Variation in the Ambulatory and Drinking Activities
after Repeated Administration of Cocaine in Rats</BLOCKQUOTE>
<BR>
P-8-15 Fukuyama, Hiroo 
<BLOCKQUOTE>The Role of Dopamine System in the Striatum on the Light Pulse
Induced PRCS</BLOCKQUOTE>
<BR>
P-9-1 Lahti, Robert 
<BLOCKQUOTE>A Differing Properties of Dopamine Agonists and Partial Agonists
at the Cloned Human D21 and D4.4 Receptors</BLOCKQUOTE>
<BR>
P-9-2 Kim, Kwang-Soo Fos-like 
<BLOCKQUOTE>Immunoreactivity in the Rat Brain Induced by Clozapine, Risperidone,
Haloperidol, and Haloperidol Combined with Antidepressant</BLOCKQUOTE>
<BR>
P-9-3 Robertson, George S 
<BLOCKQUOTE>Similar Effects of Chronic Clozapine and 'Seroquel' (ICI 204,
636) Administration on DeltaFosB Expression in the Forebrain</BLOCKQUOTE>
<BR>
P-9-4 Narita, Minoru 
<BLOCKQUOTE>Effect of YM-43611 and Neuroleptics on C-FOS Expression in the
Rat Forebrain</BLOCKQUOTE>
<BR>
P-9-5 Fibiger, Hans C 
<BLOCKQUOTE>Receptor Mechanisms Mediating Clozapine-Induced C-FOS Expression</BLOCKQUOTE>
<BR>
P-9-6 Koshiya, Kazuo 
<BLOCKQUOTE>Differential Roles of D2, D3 and D4 Receptors in Dopamine- Related
,Behaviours as Assessed With a Novel D3/D4 Antagonist YM-43611</BLOCKQUOTE>
<BR>
P-9-7 Nakamura, Mitsutaka 
<BLOCKQUOTE>Dopamine D2 Receptor Change after Repeated Treatment with SM-9018,
a Novel Neuroleptic</BLOCKQUOTE>
<BR>
P-9-8 Tang, Siu W 
<BLOCKQUOTE>Is Clozapine a Dopaminergic Drug?</BLOCKQUOTE>
<BR>
P-9-9 Heal, David J 
<BLOCKQUOTE>Comparison of the Pharmacological Profiles of Zotepine and Norzotepine</BLOCKQUOTE>
<BR>
P-9-10 Heal, David J 
<BLOCKQUOTE>BTS 73 947, A Novel D1/D5 Antagonist with Predicted Atypical
Antipsychotic Activity</BLOCKQUOTE>
<BR>
P-9-11 Kikuchi, Tetsuro 
<BLOCKQUOTE>Behavioural Studies of OPC-14597, A Novel Antipsychotic Drug</BLOCKQUOTE>
<BR>
P-9-12 Inazu, Masato 
<BLOCKQUOTE>Pharmacological Profile of PR-000608, a Novel Dopamine Uptake
Inhibitor</BLOCKQUOTE>
<BR>
P-9-13 Trimble, Karen M 
<BLOCKQUOTE>The Effects of Clozapine and Remoxipride on Latent Inhibition
in Rats</BLOCKQUOTE>
<BR>
P-9-14 Ellenbroek, Bart 
<BLOCKQUOTE>'Seroquel' (ICI 204, 636) and Clozapine are Effective in an
Animal Model of the Negative Symptoms of Schizophrenia</BLOCKQUOTE>
<BR>
P-9-15 Bergman, Jack 
<BLOCKQUOTE>Clozapine-Like Behavioural Effects of 'Seroquel' (ICI 204, 636)
in Squirrell Monkeys</BLOCKQUOTE>
<BR>
P-9-16 Goldstein, Jeffrey M 
<BLOCKQUOTE>Pharmacology of 'Seroquel' (ICI 204, 636): An Atypical Dibenzothiazepine
Antipsychotic</BLOCKQUOTE>
<BR>
P-9-17 Takeuchi, Hisako 
<BLOCKQUOTE>Response of Animal Model for Tardive Dyskinesia to Central Drugs</BLOCKQUOTE>
<BR>
P-9-18 Swerdlow, Neal R 
<BLOCKQUOTE>Seroquel Restores Prepulse Inhibition of Startle in Phencycldine-Treated
Rats</BLOCKQUOTE>
<BR>
P-9-19 Noda, Yukihiro 
<BLOCKQUOTE>Phencyclidine-induced Schizophrenia Negative Symptom-Like Behaviour
in Mice: Comparative Study of Risperidone and Haloperidol</BLOCKQUOTE>
<BR>
P-9-20 Scalzo, Frank M 
<BLOCKQUOTE>Effects of Developmental PhecyclidineExposure on Auditory Startle
and Locomotor Activity</BLOCKQUOTE>
<BR>
P-9-21 Oyamada, Takahiro 
<BLOCKQUOTE>Effect of Dantrolene on Caffeine-induced Dopamine Release in
Rat Striatum</BLOCKQUOTE>
<BR>
P-9-22 Davidson, Bruce C 
<BLOCKQUOTE>Lipoxygenase Pathway Modulation of Dopamine Release</BLOCKQUOTE>
<BR>
P-9-23 Semba, Jun'Ichi 
<BLOCKQUOTE>Effect of Glutamate Uptake Inhibitor L-Trans-PDC on Amino Acids
in Rat Striatum: Microdialysis Study</BLOCKQUOTE>
<BR>
P-9-24 Javaid, J I 
<BLOCKQUOTE>Dopaminergic Modulation of GABA Release: In Vivo Microdialysis
in Freely Moving Rats</BLOCKQUOTE>
<BR>
P-9-25 Kodama, Yoshio 
<BLOCKQUOTE>Changes of Monoamine Synapses and Behaviour in Rats Induced
By Fetel Injection of Methylazoxymethanol</BLOCKQUOTE>
<BR>
P-9-26 Zlenko, Helen 
<BLOCKQUOTE>The Peculiarities of the Meperedine Action in Early Ontogenesis</BLOCKQUOTE>
<BR>
P-9-27 Ito, Chihiro 
<BLOCKQUOTE>Inhibitory Role of Brain Histaminergic Neuron System on Behavioural
Sensitization</BLOCKQUOTE>
<BR>
P-9-28 Rehavi, Moshe 
<BLOCKQUOTE>Gonadal Hormones and the Presynaptic Transporters For Dopamine
and Serotonin in Rat Brain</BLOCKQUOTE>
<BR>
P-9-29 Tanaka, Masatoshi 
<BLOCKQUOTE>Activation of Noradrenergic Neurons in the Rat Locus Coeruleus
and Noradrenaline Release in the Amygdala</BLOCKQUOTE>
<BR>
P-9-30 Chekhonin, Vladimir P 
<BLOCKQUOTE>Anti-Alpha2-GP and Anti-GFAP Antibodies as the Vectors for Targeted
Delivery of Haloperidol intothe Glial Cells</BLOCKQUOTE>
<BR>
P-10-1 Maguire, Kay P 
<BLOCKQUOTE>Platelet Paroxetine Binding in Post-Traumatic Stress Disorder</BLOCKQUOTE>
<BR>
P-10-2 Le Poncin, Monique 
<BLOCKQUOTE>Experimental Study: Stress and Memory</BLOCKQUOTE>
<BR>
<BR>
P-10-3 Sasuga, Yasuo 
<BLOCKQUOTE>Interaction of Glucocorticoid Receptor With Heat Shock Protein
90 After Chronic Stress</BLOCKQUOTE>
<BR>
P-10-4 Sergeyev, Vladimir S 
<BLOCKQUOTE>Effect of Dilithium N-Acetyl-L-Aspartate on Stress-Induced Dopamine
Release in Hypothalamus</BLOCKQUOTE>
<BR>
P-10-5 Tsujimaru, Shusaku 
<BLOCKQUOTE>Stress-Induced Phase-Shifts in the Locomotor Activity Rhythm
and Increases in Noradrenaline Turnover in the Locus Coeruleus Region</BLOCKQUOTE>
<BR>
P-10-6 Asou, Tadafumi 
<BLOCKQUOTE>The Effect of Prenatal Stress on the Development of the Rat
Aminergic Receptors and Behaviour</BLOCKQUOTE>
<BR>
P-10-7 Izumi, Takeshi 
<BLOCKQUOTE>Effects of Acute and Chronic Administration of CCKb Antagonist
on Conditioned Fear Stress</BLOCKQUOTE>
<BR>
P-10-8 Seredenin, Sergey B 
<BLOCKQUOTE>Pharmacological Regulation of Anxiety in Dependence on Stress
Reaction Phenotype</BLOCKQUOTE>
<BR>
P-10-9 Nardi, Antonio E 
<BLOCKQUOTE>Comorbidity and Treatment Features in Social Phobia</BLOCKQUOTE>
<BR>
P-10-10 Bisserbe, Jean-Claude 
<BLOCKQUOTE>Sertraline in Obsessive-Compulsive Spectrum Disorders - A Case
Study Series</BLOCKQUOTE>
<BR>
P-10-11 Bisserbe, Jean-Claude 
<BLOCKQUOTE>Effect Size, Placebo Response and Tolerability in Clinical Studies
in Obsessive-Compulsive Disorder</BLOCKQUOTE>
<BR>
P-10-12 Avedisova, Alla S 
<BLOCKQUOTE>Generalized Anxiety (GA) and Panic Attacks (PA): The Pathogenic
Targets for Psychopharmacology</BLOCKQUOTE>
<BR>
P-10-13 Balkom, Anton J.L.M. van 
<BLOCKQUOTE>Two-Year Follow-Up After Treatment of Panic Disorder with Agoraphobia</BLOCKQUOTE>
<BR>
P-10-14 Wolkow, Robert M 
<BLOCKQUOTE>Double-Blind Comparison of Sertraline and Placebo in Patients
with Panic Disorder</BLOCKQUOTE>
<BR>
P-10-15 Corrigan, Mark H 
<BLOCKQUOTE>Can Panic Disorder Patients Treated With More Than 4mg/day of
Alzrazolam Reduce Their Dose?</BLOCKQUOTE>
<BR>
P-10-16 Judge, Rajinder 
<BLOCKQUOTE>Efficacy and Safety of Paroxetine in Panic Disorder</BLOCKQUOTE>
<BR>
P-10-17 Wolkow, Robert M 
<BLOCKQUOTE>Double-Blind Flexible Dose Study of Sertraline and Placebo in
Patients with Panic Disorder</BLOCKQUOTE>
<BR>
P-10-18 Gunnarsson, Tove 
<BLOCKQUOTE>CCK-4 in Cerebrospinal Fluid: A Pilot Study in Healthy Male
Volunteers</BLOCKQUOTE>
<BR>
P-10-19 Le Melledo, Jean-Michel 
<BLOCKQUOTE>Effect of a Major Depressive EpisodeHistory on the CCK-4 Response
in Women</BLOCKQUOTE>
<BR>
P-10-20 Le Melledo, Jean-Michel 
<BLOCKQUOTE>The Role of the Beta Adrenergic System in CCK-4 Induced Panic
Symptoms</BLOCKQUOTE>
<BR>
P-10-21 Miyamoto, Masafumi 
<BLOCKQUOTE>Mutation in the Cholecystokinin B Receptor in Panic Disorder</BLOCKQUOTE>
<BR>
P-10-22 Akiyoshi, Jotaro 
<BLOCKQUOTE>CCK-4-Induced Calcium Mobilization in T Cells is Enhanced in
Panic Disorder</BLOCKQUOTE>
<BR>
P-10-23 Isogawa, K 
<BLOCKQUOTE>Effect of Provoking Panic Attack Agents on Extracellular Level
of 5-Hydroxytryptamine in Hippocampus of Free Moving Rats</BLOCKQUOTE>
<BR>
P-10-24 Trist, David G 
<BLOCKQUOTE>Anziolytic Activity of GV 150013, A New Potent and Selective
Cholecystokinin-B (CCK-B) Antagonist</BLOCKQUOTE>
<BR>
P-10-25 Inada, Yasushi 
<BLOCKQUOTE>An Association Study Between Panic Disorder and Setotonin 2C
Receptor DNA Marker</BLOCKQUOTE>
<BR>
P-10-26 Blackburn, Tom 
<BLOCKQUOTE>P 5-HT2C Receptor Antagonists and Anxiety Disorders</BLOCKQUOTE>
<BR>
P-10-27 Mizuki, Yasushi 
<BLOCKQUOTE>Anziolytic Effects of Y-23684 in Normal Humans With High- and
Low-Anxiety</BLOCKQUOTE>
<BR>
P-10-28 Leander, J. David 
<BLOCKQUOTE>Anticonvulsant and Anxiolytic Effects of LY300164, an Orally
Effective AMPA Antagonist</BLOCKQUOTE>
<BR>
P-10-29 Leonsegui, 
<BLOCKQUOTE>Indalecio Benzodiazepine - Mediated Overactivation of 5-HT2
Behavioural Responses in Rodents</BLOCKQUOTE>
<BR>
P-10-30 Norman, Trevor R 
<BLOCKQUOTE>Benzopiazepine - Serotonin Receptor Interactions: Studies in
Animal Behavioural Models</BLOCKQUOTE>
<BR>
P-10-31 Sedman, Gary 
<BLOCKQUOTE>Activity of 5HT-3 Receptor Active Compounds in Animal Behavioural
Models of Anxiety</BLOCKQUOTE>
<BR>
P-10-32 Gracey, David J 
<BLOCKQUOTE>The Effects of the CCK Antagonist, Proglumide, On Latent Inhibition
in Rats</BLOCKQUOTE>
<BR>
P-10-33 Nagatani, Tadashi 
<BLOCKQUOTE>AP521, a Novel Benzothieno-pyridine Derivative, Shows Anxiolytic
Activity</BLOCKQUOTE>
<BR>
P-10-34 Kalueff, Allan V 
<BLOCKQUOTE>Bimodal Effects of GABAergic Drug Penicillin on Anxiety</BLOCKQUOTE>
<BR>
P-10-35 Kalueff, Allan V 
<BLOCKQUOTE>Modulation of Grooming Behaviour by GABAergic Drug Penicillin</BLOCKQUOTE>
<BR>
P-10-36 Denisenko, Peter P 
<BLOCKQUOTE>New Day Tranquilizer - Tarden</BLOCKQUOTE>
<BR>
P-10-37 Wilner, Keith 
<BLOCKQUOTE>Anxiolytic Effects of Ziprasidone Compared with Diazepam and
Placebo Prior to Dental Surgery</BLOCKQUOTE>
<BR>
P-10-38 Starmark, Jan-Erik 
<BLOCKQUOTE>Anxiety-Depressive Disorders After Subarachnoid Hemorrhage (SAH):
Association with Fatibuability</BLOCKQUOTE>
<BR>
P-11-1 Elliot, Elizabeth E 
<BLOCKQUOTE>Gender Differences in Body Temperature During Lorazepam Tolerance
and Withdrawal</BLOCKQUOTE>
<HR>P-11-2 Lemoine, Patrick 
<BLOCKQUOTE>Withdrawal of Lorazepam Long-Term Administred Using Six Different
Plans</BLOCKQUOTE>
<BR>
P-11-3 Shulman, Albert 
<BLOCKQUOTE>Mechanistic Studies with Addictive Sedative-Hypnotics and Related
Drugs in the Mouse</BLOCKQUOTE>
<BR>
P-11-4 Sedman, Gary 
<BLOCKQUOTE>An Animal Model of Benzodiazepine Withdrawal: The Effect of
uHT-1C Receptor Active Compounds</BLOCKQUOTE>
<BR>
P-11-5 Toki, Sadamu 
<BLOCKQUOTE>Relationship Between Diazepam Withdrawal Signs and GABA Receptor
Function in Rats</BLOCKQUOTE>
<BR>
P-11-6 Parrott, Andrew C 
<BLOCKQUOTE>Cognitive Performance and Mood Changes Over 24 Hours of Smoking
Abstinence</BLOCKQUOTE>
<BR>
P-11-7 Nishimoto, Masahiko 
<BLOCKQUOTE>The Effects of Nicotine on the ColorWord Test</BLOCKQUOTE>
<BR>
P-11-8 Merlo-Pich, Emilio 
<BLOCKQUOTE>EMP Central Nervous System Disribution of C-Fos Expression in
a Rat Model of Nicotine Craving</BLOCKQUOTE>
<BR>
P-11-9 Yanagita, Tomoji 
<BLOCKQUOTE>Neural Mechanisms of Dependence on and Psychotoxicity of Nicotine</BLOCKQUOTE>
<BR>
P-11-10 Baumann, Pierre 
<BLOCKQUOTE>Carbamazepine-Mianserin in Opiate Withdrawal Study: A Double
Blind Study Versus Clonidine</BLOCKQUOTE>
<BR>
P-11-11 Broadbear, Jillian H 
<BLOCKQUOTE>Alternative Pharmacotherapies in the Treatment of Opioid Addiction</BLOCKQUOTE>
<BR>
P-11-12 Torrens, Marta 
<BLOCKQUOTE>Methadone Plasma Levels in a Methadone Maintenance Treatment</BLOCKQUOTE>
<BR>
P-11-13 Iwasa, Hiroto 
<BLOCKQUOTE>The mRNA Expression of G Protein Subclasses in the Methamphetamine-Induced
Behavioural Sensitization</BLOCKQUOTE>
<BR>
P-11-14 Shabanov, Peter D Dopaminergic 
<BLOCKQUOTE>Modulation of Hypothalamic Self-Stimulation of Socially Isolated
Rats with Lesions of Brain Mesolimbic Structures</BLOCKQUOTE>
<BR>
P-11-15 Hunt, Glenn E 
<BLOCKQUOTE>Induction of Immediate Early Genes Following Rewarding Brain
Stimulation</BLOCKQUOTE>
<BR>
P-11-16 Gawin, Frank H 
<BLOCKQUOTE>Flupenthixol and Desipramine Treatment of Crack Users: Double
Blind Results</BLOCKQUOTE>
<BR>
P-11-17 Fagemo, Ingalill 
<BLOCKQUOTE>Incidence of Drug Dependence in Employees with Long Term Sick
Leave in the Municipality of Trollhatten</BLOCKQUOTE>
<BR>
P-12-1 Magnus, Ryan 
<BLOCKQUOTE>Minimum Effective Doses of SSRIs</BLOCKQUOTE>
<BR>
P-12-2 Preskorn, Sheldon H 
<BLOCKQUOTE>The SSRI Withdrawal Syndrome</BLOCKQUOTE>
<BR>
P-12-3 Lane, Roger 
<BLOCKQUOTE>Effects of SSRIs on Cognitive Function</BLOCKQUOTE>
<BR>
P-12-4 Bisserbe, Jean-Claude 
<BLOCKQUOTE>Predictors of Response to SSRIs in Patients with Major Depression</BLOCKQUOTE>
<BR>
P-12-5 Judge, Rajinder 
<BLOCKQUOTE>Clinical Experience With Paroxetine: A Review</BLOCKQUOTE>
<BR>
P-12-6 Freed, E A 
<BLOCKQUOTE>Double-Blind Multicentre Comparison of Paroxetine and Amitriptyline
in Australian General Practice</BLOCKQUOTE>
<BR>
P-12-7 Lee, Hong-Shick 
<BLOCKQUOTE>Antidepressant Effects of Paroxetine in Korean Patients With
Major Depression</BLOCKQUOTE>
<BR>
P-12-8 Hawley, Chris 
<BLOCKQUOTE>A Review of the Psychomotor Effects of Paroxetine</BLOCKQUOTE>
<BR>
P-12-9 Keller, Martin B 
<BLOCKQUOTE>Cross-Over Study of Sertraline Versus Imipramine in Chronic
Depression</BLOCKQUOTE>
<BR>
P-12-10 Kocsis, James H 
<BLOCKQUOTE>Sertraline Versus Imipramine in the Acute and Continuation Treatment
of Dysthymia</BLOCKQUOTE>
<BR>
P-12-11 Lepine, Jean-Pierre 
<BLOCKQUOTE>Treatment of Severe Major Depression: A Double-Blind Study of
Sertraline and Clomipramine</BLOCKQUOTE>
<BR>
P-12-12 Bugarski-Kirola, Dragara 
<BLOCKQUOTE>The Efficacy of Sertraline in the Treatment of Major Depression</BLOCKQUOTE>
<BR>
P-12-13 Montgomery, Stuart 
<BLOCKQUOTE>A Setraline in Continuation Therapy</BLOCKQUOTE>
<BR>
P-12-14 Lista Varela, Alvaro 
<BLOCKQUOTE>Sexual Side Effects During Sertraline Treatment of Patients
with Major Depression: A Naturalistic Study</BLOCKQUOTE>
<BR>
P-12-15 Latimer, Paul R 
<BLOCKQUOTE>A Six Month Comparison of Toleration and Efficacy of Sertraline
and Fluoxetine Treatment of Major Depression</BLOCKQUOTE>
<BR>
P-12-16 Sechter, D 
<BLOCKQUOTE>A Double Blind Comparison of Sertraline and Fluoxetine in the
Treatment of Major Depressive Episode in Out Patient</BLOCKQUOTE>
<BR>
P-12-17 Dittmann, Ralf W 
<BLOCKQUOTE>Psychotropic Comedication and Adverse Event Rates, Results from
a Fluoxetine Drug Surveillance Study</BLOCKQUOTE>
<BR>
P-12-18 Jakovljevic, Miro 
<BLOCKQUOTE>Serotonergic (Fluoxetine) Versus Noradrenergic (Maprotiline)
Antidepressants and Suicidality</BLOCKQUOTE>
<BR>
P-12-19 Bhaumik, Sabyasachi 
<BLOCKQUOTE>Outcomes Incl.Withdrawal Phenomena Detected From a Naturalistic
Comparison of Fluoxetine&amp;Paroxetine Used in the Treatment of Affective
Disorders in Patients With LearningDisabilities</BLOCKQUOTE>
<BR>
P-12-20 Lavergne, Francis O 
<BLOCKQUOTE>Clinical Differences in Response to Mianserin and Fluoxetine
in Depressive Patients</BLOCKQUOTE>
<BR>
P-12-21 Biondi, Franco 
<BLOCKQUOTE>Preliminary Results of a Randomized Double Blind Study of Amisulpride
VS Fluoxetine in 281 Dysthymic Patients</BLOCKQUOTE>
<BR>
P-12-22 Vujic, Dunja L 
<BLOCKQUOTE>Efficacy and Tolerability of Fluoxetine Compared With Maprotiline
in Major Depressive Episode: Results of Central- East European Study</BLOCKQUOTE>
<BR>
P-12-23 Zanardi, Raffaella 
<BLOCKQUOTE>Fluvoxamine Alone in the Treatment of Delusional Depression</BLOCKQUOTE>
<BR>
P-12-24 Radics, Judith 
<BLOCKQUOTE>Effectiveness of Fluvoxamine Therapy in Cardiological Patients
Suffering From Depression</BLOCKQUOTE>
<BR>
P-12-25 Zanardi, Raffaella 
<BLOCKQUOTE>Fluvoxamine and Lithium in Long-Term Treatment of Unipolar Subjects</BLOCKQUOTE>
<BR>
P-12-26 Dinan, Timothy G Dex 
<BLOCKQUOTE>Augmentation of Sertraline Response in Resistant Depression</BLOCKQUOTE>
<BR>
P-12-27 Edstrom, Anders Buspiron 
<BLOCKQUOTE>Augmentation of SSRI Therapy in Treatment-Refractory Depression</BLOCKQUOTE>
<BR>
P-12-28 Hawley, Chris 
<BLOCKQUOTE>Safety and Tolerability of Combined Treatment with Moclobemide
and SSRIs: A Preliminary Study</BLOCKQUOTE>
<BR>
P-12-29 Grounds, David 
<BLOCKQUOTE>Use of Combined SSRIs and Moclobemide in Treatment-Resistant
Depression</BLOCKQUOTE>
<BR>
P-12-30 Hawley, Chris 
<BLOCKQUOTE>A Protocol for the Pharmacologic Treatment of Major Depression</BLOCKQUOTE>
<BR>
P-12-31 Mantonakis, John E 
<BLOCKQUOTE>Compliance to Psychopharmacological Treatment: Suggestions For
Its Improvement</BLOCKQUOTE>
<BR>
P-12-32 Nicolini, Humberto 
<BLOCKQUOTE>Temperament, Character and Molecular Genotypes as Predictors
of Antidepressant Response</BLOCKQUOTE>
<BR>
P-12-33 Preskorn, Sheldon H Polypharmacy: What is its Role in the<BR>
Long-Term Use of Antidepressants?<BR>
<BR>
P-12-34 Russell, James M 
<BLOCKQUOTE>Economic Impact of Improved Work Performance After Treatment
of Chronic Depression</BLOCKQUOTE>
<BR>
P-12-35 Bennett, Kathryn 
<BLOCKQUOTE>Utility-Based Measures of Health-Related Quality of Life in
Depression</BLOCKQUOTE>
<BR>
P-12-36 Zivkovic-Milovanovic, Djurdjinka 
<BLOCKQUOTE>Dexamethasone Suppression Test in Depression</BLOCKQUOTE>
<BR>
P-12-37 Ohara, Koichi 
<BLOCKQUOTE>5-HT2A Receptor Gene Intact in Mood Disorder</BLOCKQUOTE>
<BR>
P-12-38 Hayashida, Masaki 
<BLOCKQUOTE>Anticipation and Repetitive Elements of the Serotonin Transporter
Gene in Affective Disorder</BLOCKQUOTE>
<BR>
P-12-39 Tsujimura, Toru 
<BLOCKQUOTE>Platelet Serotonin2 Receptor Binding in Affective Disorders</BLOCKQUOTE>
<BR>
P-12-40 Kasahara, Tomoyuki 
<BLOCKQUOTE>Strong and Long-Lasting Inhibition of 5-HT Uptake of Platelets
in Subjects treated by Duloxetine, an Antidepressant Candidate</BLOCKQUOTE>
<BR>
P-12-41 Smith, Katharine A 
<BLOCKQUOTE>Tryptophan Depletion in Recovered Depressives and Recovered
Bulimics</BLOCKQUOTE>
<BR>
P-12-42 Timotijevic, Ivana 
<BLOCKQUOTE>Therapeutic Advantage of Combined Amitriptyline/Lithium and
Fluvoxamine/Lithium Treatments</BLOCKQUOTE>
<BR>
P-13-1 Muller, Norbert 
<BLOCKQUOTE>Saccadic Eye Movements in Gilles-de-la-Tourette-Syndrome</BLOCKQUOTE>
<BR>
P-13-2 Ginovart, Nathalie 
<BLOCKQUOTE>In Vivo Examination of the Pre-and Postsynaptic Dopamine Neurons
in Huntingon's Disease</BLOCKQUOTE>
<BR>
P-13-3 Tai, Chih-Ta 
<BLOCKQUOTE>The Effects of Cues on Executive Functions of Parkinsonian Patients</BLOCKQUOTE>
<BR>
P-13-4 Meco, Giuseppe Tolcapone 
<BLOCKQUOTE>Therapy Improves Cognitive Functions in Nondemented Patients
with Advanced Parkinson's Disease</BLOCKQUOTE>
<BR>
P-13-5 Meco, Giuseppe 
<BLOCKQUOTE>Acute Administration of Levodopa and Carbidopa Before and After
Four Months Treatment with Tolcapone in Advanced Parkinson's Disease</BLOCKQUOTE>
<BR>
P-13-6 Meco, Giuseppe 
<BLOCKQUOTE>Risperidone in Levodopa Induced Psychosis in Advanced Parkinson's
Disease. An Open Label, Long-Term Study</BLOCKQUOTE>
<BR>
P-13-7 Marchesi, Gian Franco 
<BLOCKQUOTE>Parkinsonism, Negative Symptomatology and Patient's Subjective
Experience</BLOCKQUOTE>
<BR>
P-13-8 Gardos, George 
<BLOCKQUOTE>A Fifteen Year Follow-Up Study of Tardive Dyskinesia and Drug
Induced Parkinsonism</BLOCKQUOTE>
<BR>
P-13-9 Uwahodo, Yasufumi 
<BLOCKQUOTE>Effects of OPC-14117 on Dopaminergic Neuronal Degeneration Induces
By MPTP</BLOCKQUOTE>
<BR>
P-13-10 Marsalek, Michal 
<BLOCKQUOTE>Awareness of Tardive Dyskinesia and Its Relationship to Tardive
Dysmentia</BLOCKQUOTE>
<BR>
P-13-11 Shriqui, Christian L 
<BLOCKQUOTE>Cognitive Impairment and Tardive Dyskinesia</BLOCKQUOTE>
<BR>
P-13-12 Street, Jamie S 
<BLOCKQUOTE>Long-Term Treatment-Emergent Dyskinetic Symptoms in Patients
Treated with Olanzapine and Haloperidol</BLOCKQUOTE>
<BR>
P-13-13 Yamaguchi, Noboru 
<BLOCKQUOTE>Ratio of Neuroleptic to Anticholinergic Level and Extrapyramidal
Symptoms Induced By Nemonapride</BLOCKQUOTE>
<BR>
P-13-14 Houchin, Jane Alathisia, 
<BLOCKQUOTE>Iron and Cortisol</BLOCKQUOTE>
<BR>
P-14-1 Theinhaus, Ole J 
<BLOCKQUOTE>The Irritability Rating Scale:Validation Data</BLOCKQUOTE>
<BR>
P-14-2 Ait-Ameur, Abderrafi 
<BLOCKQUOTE>Continuous Infusion of Haloperidol and Delerium in Intensive
Care Unit</BLOCKQUOTE>
<BR>
P-14-3 Ramseier, Fritz J 
<BLOCKQUOTE>Blue Notes (On Physicians Noncompliance)</BLOCKQUOTE>
<BR>
P-14-4 Kopylova, Galina N 
<BLOCKQUOTE>Analgetic Properties of Some Prolin Containing Oligopeptides,
Having Antiulcer Effect</BLOCKQUOTE>
<BR>
P-14-5 Oga, Kentaro Ketamine: 
<BLOCKQUOTE>Neurophysiological Study of Subanesthetic Doses in Patients
with Chronic Pain</BLOCKQUOTE>
<BR>
P-14-6 Davydova, Nataly 
<BLOCKQUOTE>A The Influence of Ketamine Pharmacokinetics on the Activity
of Neurotransmitter Systems in Humans Under Surgical Stress</BLOCKQUOTE>
<BR>
P-14-7 Karlov, Vladimiz A Functional State of the System 
<BLOCKQUOTE>DOPHA-Dophamini (DA)- Noradrenalini (NA)-Adremalini (A) Under
Epilepsy</BLOCKQUOTE>
<BR>
P-14-8 Gentil, Valentim V 
<BLOCKQUOTE>Psychiatric Morbidity in Candidates for Normal Volunteer Trials</BLOCKQUOTE>
<BR>
<HR>
<P><CENTER><A HREF="index.htm#anchor689408"><IMG SRC="files.gif/smanlog.gif"
WIDTH="62" HEIGHT="57" ALIGN="BOTTOM" NATURALSIZEFLAG="3"></A></CENTER>
</BODY>
</HTML>
</DOC>